Insider · CIK 0001975022
Elizabeth Rozek
Files at SGMT (Sagimet Biosciences Inc.). First filing Jul 23, 2025, latest Jul 22, 2026.
In brief
Elizabeth Rozek files SEC Form 4 as officer at SGMT (Sagimet Biosciences Inc.). Since Jul 23, 2025, Elizabeth Rozek has reported 0 open-market buys worth $0 and 3 open-market sells worth $194k, the latest filed on Jul 22, 2026.
A track record needs three past buys with six months of prices behind them; Elizabeth Rozek has 0, so none is measured yet.
The newest scored trade: sold $82k of SGMT on Jul 20, 2026, filed Jul 22, 2026, scored 39 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $96k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SGMT: Sagimet Biosciences Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Sagimet Biosciences Inc. | $82k 10,545 shares | -4% | +57% from low-30% from high | |
| 30Weak | Sagimet Biosciences Inc. | $14k 2,622 shares | -1% | +197% from low-45% from high | |
| 40Moderate | Sagimet Biosciences Inc. | $98k 10,780 shares | -6% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | SGMT Sagimet Biosciences Inc. | SOpen-market sale Series A Common Stock | -10,545 | $7.76 | $82k | 224,414 | Jul 22, 2026 |
| May 28, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Jun 1, 2026 |
| Feb 19, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Series A Common Stock | +44,000 | $0.00 | $0 | 234,959 | Feb 20, 2026 |
| Feb 19, 2026 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +88,000 | $0.00 | $0 | 88,000 | Feb 20, 2026 |
| Feb 10, 2026 | SGMT Sagimet Biosciences Inc. | SOpen-market sale Series A Common Stock | -2,622 | $5.36 | $14k | 190,959 | Feb 12, 2026 |
| Nov 4, 2025 | SGMT Sagimet Biosciences Inc. | AGrant or award Series A Common Stock | +9,855 | $0.00 | $0 | 193,581 | Nov 6, 2025 |
| Nov 4, 2025 | SGMT Sagimet Biosciences Inc. | AGrant or award Stock Option (Right to Buy)derivative | +13,367 | $0.00 | $0 | 13,367 | Nov 6, 2025 |
| Jul 21, 2025 | SGMT Sagimet Biosciences Inc. | SOpen-market sale Series A Common Stock | -10,780 | $9.13 | $98k | 183,726 | Jul 23, 2025 |
| Nov 17, 2023 | SGMT Sagimet Biosciences Inc. | AGrant or award Series A Common Stock | +171,420 | $0.00 | $0 | 171,420 | Nov 21, 2023 |
Questions about Elizabeth Rozek
Answered from the filings on this page, as of the latest one.
Is Elizabeth Rozek buying or selling?
In the last 12 months Elizabeth Rozek reported 0 open-market buys worth $0 and 2 open-market sells worth $96k on SEC Form 4; the latest was sold $82k of SGMT on Jul 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Elizabeth Rozek's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Elizabeth Rozek has 0.
Where does Elizabeth Rozek file Form 4?
Elizabeth Rozek has filed Form 4 at SGMT (Sagimet Biosciences Inc.) as General Counsel and CCO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.